OPHARMIC TECHNOLOGY (HK) LIMITED Completes New Round of Financing and Files Prospectus

"Thanks to the trust and support from the Hong Kong Biotechnology Fund and existing shareholders. The Opharmic team, with its deep technical expertise and continuous innovative spirit, is committed to expanding the application of ultrasound technology platforms in drug delivery and cell activation fields. This round of financing will accelerate the commercialization process of our ultrasound drug delivery technology platform in ophthalmology and immunotherapy treatment areas, and promote the R&D and production of cell therapy projects. With outstanding ultrasound engineering R&D capabilities, Opharmic Technology (HK) Limited is determined to become a globally leading medical technology enterprise, providing efficient and innovative high-value solutions for the drug delivery and cell therapy fields."

"Opharmic addresses major indications such as fundus diseases by utilizing ultrasound for non-invasive delivery of macromolecular drugs, resolving clinical pain points like adverse reactions and poor compliance caused by intravitreal injections, making it an excellent application scenario."

The Opharmic project is a very typical case of the commercialization of scientific research results from the Hong Kong University of Science and Technology. It is one of the first batch of investment projects after the establishment of E-Fund. The fund will make full use of its ecosystem resources to empower the Opharmic project, accelerating clinical development and commercial cooperation.

In the future, the Hong Kong Biotechnology Fund will rely on the scientific research ecosystem resources of Shanghai and Hong Kong, continue to invest in high-tech, high-barrier projects with FIC/BIC global leading levels that can fully synergize industrial resources, and actively contribute to the construction of Hong Kong as an international innovation and technology center.